Sign In
Buy CBAY
$32.48
+0 (+0%)
At Close: Apr 11, 2024
Here's Why Momentum in CymaBay Therapeutics Inc. (CBAY) Should Keep going
09:59am, Wednesday, 29'th Mar 2023
CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
4 Best Breakout Stocks to Buy Now for Superlative Returns
09:13am, Wednesday, 29'th Mar 2023
CymaBay Therapeutics (CBAY), RxSight (RXST), UWM (UWMC) & Remitly Global (RELY) have been selected as the breakout stocks for today.
Wall Street Analysts Predict a 40.32% Upside in CymaBay Therapeutics Inc. (CBAY): Here's What You Should Know
11:29am, Tuesday, 28'th Mar 2023
The consensus price target hints at a 40.3% upside potential for CymaBay Therapeutics Inc. (CBAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
CymaBay Therapeutics, Inc. (CBAY) Q4 2022 Earnings Call Transcript
08:43pm, Thursday, 16'th Mar 2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Paul Quinlan - General Counsel Sujal Shah - Chief Executive Officer Chuck McWh
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
04:05pm, Thursday, 09'th Mar 2023
NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dis
CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
08:00am, Wednesday, 01'st Mar 2023
NEWARK, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dis
CymaBay: Long Term Is Constructive With Potential Seladelpar Conversion
12:46am, Thursday, 23'rd Feb 2023
CymaBay caught a strong bid in early FY23 after advising its collaboration with Kaken Pharma in Japan. Its seladelpar compound has potential to create a medical breakthrough in primary biliary cholang
CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference
08:00am, Monday, 06'th Feb 2023
NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dise
5 Best and Worst Performing Small-Cap Stocks in Dec 2022
10:59pm, Tuesday, 17'th Jan 2023
Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.
CymaBay Therapeutics: Undiscovered Opportunity
06:57am, Saturday, 31'st Dec 2022
100% technical buy signals. 13 new highs and up 84.95% in the last month.
CymaBay Therapeutics, Inc. (CBAY) Q3 2022 Earnings Call Transcript
04:47am, Tuesday, 15'th Nov 2022
CymaBay Therapeutics, Inc. (NASDAQ:CBAY ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Paul Quinlan - General Counsel Sujal Shah - Chief Executive Officer Chuck M
CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
08:02am, Tuesday, 06'th Sep 2022
NEWARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dis
CymaBay Therapeutics Inc. (CBAY) Upgraded to Buy: What Does It Mean for the Stock?
01:33pm, Monday, 05'th Sep 2022
CymaBay Therapeutics Inc. (CBAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2022 Results - Earnings Call Transcript
11:16pm, Thursday, 11'th Aug 2022
Cymabay Therapeutics, Inc. (NASDAQ:CBAY ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Paul Quinlan - General Counsel, Chief Compliance Officer & Corporate Secretar
CymaBay: Long-Term Potential Based On Prior PBC Trial Results
06:52pm, Monday, 27'th Jun 2022
Results from the phase 3 RESPONSE study, which is using Seladelpar for the treatment of patients with primary biliary Cholangitis, are expected in 2023. PBC patients treated with Seladelpar over a 2-y
